Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria
Plasmodium vivax has the largest geographic range of human malaria species and is challenging to manage and eradicate due to its ability to establish a dormant liver stage, the hypnozoite, which can reactivate leading to relapse. Until recently, the only treatment approved to kill hypnozoites was th...
Saved in:
Main Authors: | Pamela L. St Jean, Gavin C.K.W. Koh, John J. Breton, Fe E.J. Espino, Tran T. Hien, Srivicha Krudsood, Marcus V.G. Lacerda, Alejandro Llanos-Cuentas, Chanthap Lon, Rezika Mohammed, Chayadol S. Namaik-Larp, Dhelio B. Pereira, David L. Saunders, Ivan D. Velez, Daniel Yilma, Maria F. Villegas, Stephan Duparc, Justin A. Green |
---|---|
Other Authors: | Oxford University Clinical Research Unit |
Format: | Article |
Published: |
2020
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/57685 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
Similar Items
-
Single-dose tafenoquine to prevent relapse of plasmodium vivax malaria
by: Marcus V.G. Lacerda, et al.
Published: (2020) -
Tafenoquine versus primaquine to prevent relapse of plasmodium vivax malaria
by: Alejandro Llanos-Cuentas, et al.
Published: (2020) -
Tafenoquine treatment of Plasmodium vivax malaria: Suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial
by: Pamela L. St Jean, et al.
Published: (2018) -
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): A multicentre, double-blind, randomised, phase 2b dose-selection study
by: Alejandro Llanos-Cuentas, et al.
Published: (2018) -
Tafenoquine: a toxicity overview
by: Cindy S. Chu, et al.
Published: (2022)